WASHINGTON - The U.S. Food and Drug Administration will consider whether to expand use of a vaccine intended to prevent cervical cancer to women aged 27 to 45, the vaccine maker said Wednesday.
Gardasil, made by Merck & Co., currently is approved for use in girls and women aged 9 through 26 to block four types of human papilloma virus, which can cause cervical cancer and genital warts.
A decision is expected by mid-year.